Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front

Cancer Science

Volumn 95, Issue 9, 2004, Pages 728-735

  Nagaike, Koki ^a   Kohama, Kazuyo ^a   Uchiyama, Shuichiro ^a   Tanaka, Hiroyuki ^a   Chijiiwa, Kazuo ^a   Itoh, Hiroshi ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPITOPE; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; KI 67 ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN ANTIBODY; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CADHERINS; CELL MEMBRANE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IN SITU HYBRIDIZATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; RABBITS; RNA, MESSENGER;

EID: 5044236063     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03253.x     Document Type: Article

References (24)

1. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 6370-6.
2. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 2003; 22: 223-36.
3. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. J Biol Chem 1993; 268: 10024-8.
4. Miyazawa K, Shimomura T, Naka D, Kitamura N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 1994; 269: 8966-70.
5. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 2000; 60: 6148-59.
6. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004; 10: 202-11.
7. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237-42.
8. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry. Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999; 96: 11054-61.
9. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, and epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-5.
10. Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem 2003; 278: 36341-9.
11. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
12. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002; 8: 1101-7.
13. Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K, Dickson RB, Lin CY, Taniguchi N. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6GlcNAc branching. J Biol Chem 2002; 277: 16960-7.
14. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K, Koono M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40453-62.
15. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 2003; 278: 26773-9.
16. Kataoka H, Suganuma T, Shimomura T, Itoh H, Kitamura N, Nabeshima K, Koono M. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues: cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999; 47: 673-82.
17. Kataoka H, Uchino H, Denda K, Kitamura N, Itoh H, Tsubouchi H, Nabeshima K, Koono M. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa. Cancer Lett 1998; 128: 219-27.
18. Shimomura T, Denda K, Kawaguchi T, Matsumoto K, Miyazawa K, Kitamura N. Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. J Biochem 1999; 126: 821-8.
19. Denda K, Shimomura T, Kawaguchi T, Miyazawa K, Kitamura N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem 2002; 277: 14053-9.
20. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y. Hepatocyte growth factor activator inhibitor type 1 and type 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 2004; 171: 890-6.
21. Itoh H, Kataoka H, Tomita M, Hamasuna R, Nawa Y, Kitamura N, Koono M. Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. Am J Physiol 2000; 278: G635-43.
22. INK4a and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 2003; 63: 1737-42.
23. INK4A and is a region of low proliferation. Am J Pathol 2001; 159: 1613-7.
24. Hiscox S, Jiang WG. Hepatocyte growth factor/scatter factor disrupts epithelial tumor cell-cell adhesion: involvement of beta catenin. Anticancer Res 1999; 19: 509-18.